Merch
Medical card
One in five U.S. adults uses CBD, yet a single FDA-approved product exists. A look at the evidence that holds up, the gaps in pain and sleep research, and the safety data you should know about.
CBD research in 2026 sits in an odd place. About 20% of American adults report using cannabidiol products, and the market keeps growing. Yet the FDA has approved one CBD product: Epidiolex, a pharmaceutical-grade epilepsy treatment. The gap between consumer adoption and clinical proof remains wide, and closing it requires sorting strong evidence from preliminary signals.
Epilepsy: The Strongest CBD Evidence Gets Stronger
Epilepsy is the condition where CBD has cleared the highest scientific bar. Epidiolex holds FDA approval for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Long-term data from the Expanded Access Program now show sustained seizure reduction through 144 weeks, extending across focal epilepsies beyond the original approved indications. Researchers continue to build on this foundation with real-world studies, including 18-month retention data from France that confirm strong outcomes even in off-label use for rare epilepsy syndromes.
This is the benchmark. Phase III randomized controlled trials, extended follow-up, pharmaceutical-grade formulation. No other CBD application comes close to this level of proof.
CBD for Anxiety: A Signal Worth Watching, Not a Settled Answer
A 2024 meta-analysis in Psychiatry Research found a significant anxiolytic effect for CBD, with a large effect size (Hedges’ g = -0.92). That number looks impressive until you count the studies behind it: eight articles, 316 total participants. A separate systematic review of 11 randomized controlled trials found contradictory results across different anxiety disorders and dosing ranges.
The CBD dosage range in these trials varied from 30 mg to 600 mg, and the dose-response relationship may follow an inverted-U curve, meaning higher doses don’t produce stronger effects. If you’re considering CBD for anxiety, that inconsistency matters. The CBD research supports further investigation, not confident recommendations.
CBD for Pain and Sleep: Gaps Wider Than Most Consumers Expect
Pain relief is one of the most common reasons people buy CBD. The clinical data on CBD for pain, specifically CBD-alone products without significant THC, paint a different picture. A 2026 Cochrane Review of 21 studies and 2,187 participants found no clear evidence that CBD-dominant medicines achieve meaningful neuropathic pain relief. An updated systematic review in Annals of Internal Medicine covering 25 RCTs reached a similar conclusion: products with low THC-to-CBD ratios may not improve pain outcomes, and adverse events can outweigh modest benefits.
Research on CBD for sleep hasn’t kept pace with consumer demand. A 2024 review in Current Psychiatry Reports identified 21 recent studies on cannabinoids and sleep disorders and concluded the evidence base doesn’t match the scale of consumer use. Formulations combining CBD with THC showed more promise than CBD alone, which complicates the picture for anyone reaching for a CBD-only product at bedtime.
CBD Side Effects: Liver Risk and Drug Interactions
The most clinically significant CBD side effects involve the liver. The FDA ran a randomized, double-blind, placebo-controlled trial testing CBD at doses between 250 and 550 mg per day for 28 days in healthy adults taking no other medications. The result: 5.6% of participants developed liver enzyme elevations exceeding three times the normal level. This CBD liver damage signal is notable because enzyme levels rose without symptoms, meaning you may not feel the harm occurring. Levels normalized after participants stopped taking CBD.
CBD drug interaction alert: A 2024 systematic review identified 31 reports of CBD drug interactions involving 16 narrow therapeutic index medications. One controlled study found that a CBD-dominant extract increased omeprazole exposure by 207% through CYP enzyme inhibition. If you take prescription medications, talk to your doctor before adding CBD.
CBD Nano-Delivery and the Regulatory Shift Ahead
CBD’s poor oral bioavailability (an estimated 6 to 19% of the dose reaches your bloodstream) limits its therapeutic ceiling. A 2025 study in Cell Chemical Biology demonstrated a nano-micelle CBD formulation that crossed the blood-brain barrier in mice, delivering rapid neuropathic pain relief without cognitive side effects. If nano-delivery technology proves safe and effective in humans, effective doses could drop, potentially reducing the liver-safety concerns flagged by the FDA trial.
On the policy side, Executive Order 14370, signed in December 2025, directed federal agencies to accelerate marijuana rescheduling and create a new regulatory framework for hemp-derived CBD products. The order acknowledged risks from inaccurate labeling and inconsistent quality control, two problems that researchers and consumers have flagged for years.
CBD research is moving. The evidence for epilepsy keeps deepening. Anxiety clinical trials show potential but need larger, more consistent samples. Pain and sleep claims, at least for CBD-alone products, remain ahead of the data. And the safety profile, once assumed to be benign, now includes a documented liver risk at doses many consumers take. The informed path forward is watching the evidence tiers, not the marketing.
Frequently Asked Questions About CBD Research
Is CBD FDA-approved for any condition?
Yes. Epidiolex (prescription cannabidiol) is FDA-approved for three forms of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. No other CBD product has received FDA approval.
Can CBD damage your liver?
A 2025 FDA-conducted trial found that CBD at consumer-relevant doses (250 to 550 mg/day) caused liver enzyme elevations in 5.6% of healthy adults. Levels returned to normal after discontinuation, but most participants didn’t notice symptoms.
Does CBD interact with prescription medications?
Yes. CBD inhibits several CYP enzymes involved in drug metabolism. A 2024 systematic review identified interactions with 16 narrow therapeutic index medications. Consult your doctor before combining CBD with prescriptions.
Does CBD help with pain?
Current evidence for CBD-alone products (without THC) in pain management is weak. A 2026 Cochrane Review found no clear evidence that CBD-dominant medicines provide meaningful neuropathic pain relief.
Is CBD effective for anxiety?
Early results are promising. A meta-analysis found a significant anxiolytic effect, but only eight studies with 316 participants qualified for inclusion. Larger, more consistent trials are needed before researchers can make confident recommendations.
Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.
